Tal No. of Questions :7] Iepi/www.rgpvonline.com (Total No.of Printed Pages :2 api/www.rgpvenline.com - RatlNo. 6 How dothe fellowing diter? z 2) Biopharmaceutis nd pharmacokinetics PY-702 at ; mreceyisee | oo Regimen Weyer Nson tins i Examination, December 2016 i ©) Plasma protein and tissue protein binding g Pharmaceutics -IX 3 E GBiopharmaceutics & Pharmacokinetics) & 7. Witenotes on any thre of the following: i vine: Thre ours : 2) Salivary xeon os ‘Maximum Marks: 78 ©) Pitparition hypothesis Nate: i) Atemptany fve question. 6), Stimubaio of ug metabo, 5) Allguestions cary equal mas 4) Factor aeting drug response 1. 8) Howean Gl absorptonbe sided fm in vivomethads? 1) Explain the selection ees for compartment models. 2. 8), How are dosage regimen adjusted inpatients with and without rena fae? 1) Discus the factors afetng drag metabolism, 3.2) How sbioealbily deteined om blood eve data? z 3} Describe the Federal requirements relating ig i Sowa andbioogince z 2 2 i 4. a) Whatsthephamacokinet significance ofplasma og 3 concentration? 3 g b) Define Va How st determined? 3 F 5. a) Discuss the pharmaceutical factors infuencingt i Sopharmcsutia performance of gs 3 b) Explain the role of biopharmaceutics a poamacoknetics in vg formladon rem rr0 bttp:/wew.rgpvontine.com. mos uuondssnsw/elyy ———____________asamyunsdiewsnaidyy